Enterprise Value
145.6M
Cash
310.3M
Avg Qtr Burn
-23.3M
Short % of Float
18.60%
Insider Ownership
6.42%
Institutional Own.
90.78%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
4D-150 Details Diabetic macular edema | Phase 2 Data readout | |
4D-150 Details Wet age-related macular degeneration | Phase 2 Data readout | |
4D-125 Details X-linked retinitis pigmentosa | Phase 1/2 Data readout | |
4D-710 Details Cystic fibrosis | Phase 1/2 Data readout | |
4D-310 Details Fabry disease | Phase 1/2 Data readout | |
4D-110 Details Choroideremia | Phase 1 Data readout |